OBJECTIVE:Hybrid closed-loop (HCL) artificial pancreas (AP) systems are now moving from research settings to widespread clinical use. In this study, the inControl algorithm developed by TypeZero Technologies was embedded to a commercial Tandem t:slim X2 insulin pump, now called Control-IQ, paired with a Dexcom G6 continuous glucose monitor and tested for superiority against sensor augmented pump (SAP) therapy. Both groups were physician-monitored throughout the clinical trial. RESEARCH DESIGN AND METHODS: In a randomized controlled trial, 24 school-aged children (6-12 years) with type 1 diabetes (T1D) participated in a 3-day home-use trial at two sites: Stanford University and the Barbara Davis Center (50% girls, 9.6 ± 1.9 years of age, 4.5 ± 1.9 years of T1D, baseline hemoglobin A1c 7.35% ± 0.68%). Study subjects were randomized 1:1 at each site to either HCL AP therapy with the Control-IQ system or SAP therapy with remote monitoring. RESULTS: The primary outcome, time in target range 70-180 mg/dL, using Control-IQ significantly improved (71.0% ± 6.6% vs. 52.8% ± 13.5%; P = 0.001) and mean sensor glucose (153.6 ± 13.5 vs. 180.2 ± 23.1 mg/dL; P = 0.003) without increasing hypoglycemia time <70 mg/dL (1.7% [1.3%-2.1%] vs. 0.9% [0.3%-2.7%]; not significant). The HCL system was active for 94.4% of the study period. Subjects reported that use of the system was associated with less time thinking about diabetes, decreased worry about blood sugars, and decreased burden in managing diabetes. CONCLUSIONS: The use of the Tandem t:slim X2 with Control-IQ HCL AP system significantly improved time in range and mean glycemic control without increasing hypoglycemia in school-aged children with T1D during remote monitored home use.
RCT Entities:
OBJECTIVE: Hybrid closed-loop (HCL) artificial pancreas (AP) systems are now moving from research settings to widespread clinical use. In this study, the inControl algorithm developed by TypeZero Technologies was embedded to a commercial Tandem t:slim X2 insulin pump, now called Control-IQ, paired with a Dexcom G6 continuous glucose monitor and tested for superiority against sensor augmented pump (SAP) therapy. Both groups were physician-monitored throughout the clinical trial. RESEARCH DESIGN AND METHODS: In a randomized controlled trial, 24 school-aged children (6-12 years) with type 1 diabetes (T1D) participated in a 3-day home-use trial at two sites: Stanford University and the Barbara Davis Center (50% girls, 9.6 ± 1.9 years of age, 4.5 ± 1.9 years of T1D, baseline hemoglobin A1c 7.35% ± 0.68%). Study subjects were randomized 1:1 at each site to either HCL AP therapy with the Control-IQ system or SAP therapy with remote monitoring. RESULTS: The primary outcome, time in target range 70-180 mg/dL, using Control-IQ significantly improved (71.0% ± 6.6% vs. 52.8% ± 13.5%; P = 0.001) and mean sensor glucose (153.6 ± 13.5 vs. 180.2 ± 23.1 mg/dL; P = 0.003) without increasing hypoglycemia time <70 mg/dL (1.7% [1.3%-2.1%] vs. 0.9% [0.3%-2.7%]; not significant). The HCL system was active for 94.4% of the study period. Subjects reported that use of the system was associated with less time thinking about diabetes, decreased worry about blood sugars, and decreased burden in managing diabetes. CONCLUSIONS: The use of the Tandem t:slim X2 with Control-IQ HCL AP system significantly improved time in range and mean glycemic control without increasing hypoglycemia in school-aged children with T1D during remote monitored home use.
Authors: Boris Kovatchev; Stephen Patek; Eyal Dassau; Francis J Doyle; Lalo Magni; Giuseppe De Nicolao; Claudio Cobelli Journal: J Diabetes Sci Technol Date: 2009-09-01
Authors: Laurel H Messer; Gregory P Forlenza; Jennifer L Sherr; R Paul Wadwa; Bruce A Buckingham; Stuart A Weinzimer; David M Maahs; Robert H Slover Journal: Diabetes Care Date: 2018-02-14 Impact factor: 19.112
Authors: Kimberly P Garza; Aneta Jedraszko; Lindsey E G Weil; Diana Naranjo; Katharine D Barnard; Lori M B Laffel; Korey K Hood; Jill Weissberg-Benchell Journal: Diabetes Technol Ther Date: 2018-03 Impact factor: 6.118
Authors: Sue A Brown; Boris P Kovatchev; Marc D Breton; Stacey M Anderson; Patrick Keith-Hynes; Stephen D Patek; Boyi Jiang; Najib Ben Brahim; Paul Vereshchetin; Daniela Bruttomesso; Angelo Avogaro; Simone Del Favero; Federico Boscari; Silvia Galasso; Roberto Visentin; Marco Monaro; Claudio Cobelli Journal: Diabetes Technol Ther Date: 2015-01-16 Impact factor: 6.118
Authors: Daniel J DeSalvo; Patrick Keith-Hynes; Thomas Peyser; Jérôme Place; Kim Caswell; Darrell M Wilson; Breanne Harris; Paula Clinton; Boris Kovatchev; Bruce A Buckingham Journal: Diabetes Technol Ther Date: 2013-10-29 Impact factor: 6.118
Authors: Gregory P Forlenza; Orit Pinhas-Hamiel; David R Liljenquist; Dorothy I Shulman; Timothy S Bailey; Bruce W Bode; Michael A Wood; Bruce A Buckingham; Kevin B Kaiserman; John Shin; Suiying Huang; Scott W Lee; Francine R Kaufman Journal: Diabetes Technol Ther Date: 2018-12-26 Impact factor: 6.118
Authors: Marc D Breton; Daniel R Cherñavvsky; Gregory P Forlenza; Mark D DeBoer; Jessica Robic; R Paul Wadwa; Laurel H Messer; Boris P Kovatchev; David M Maahs Journal: Diabetes Care Date: 2017-08-30 Impact factor: 19.112
Authors: Laya Ekhlaspour; Gregory P Forlenza; Daniel Chernavvsky; David M Maahs; R Paul Wadwa; Mark D Deboer; Laurel H Messer; Marissa Town; Jennifer Pinnata; Geoff Kruse; Boris P Kovatchev; Bruce A Buckingham; Marc D Breton Journal: Pediatr Diabetes Date: 2019-05-23 Impact factor: 4.866
Authors: Katarina Braune; Rayhan A Lal; Lenka Petruželková; Gary Scheiner; Per Winterdijk; Signe Schmidt; Linda Raimond; Korey K Hood; Michael C Riddell; Timothy C Skinner; Klemens Raile; Sufyan Hussain Journal: Lancet Diabetes Endocrinol Date: 2021-11-13 Impact factor: 32.069
Authors: Rodolfo J Galindo; Roy W Beck; Maria F Scioscia; Guillermo E Umpierrez; Katherine R Tuttle Journal: Endocr Rev Date: 2020-10-01 Impact factor: 19.871
Authors: Gregory P Forlenza; Bruce A Buckingham; Sue A Brown; Bruce W Bode; Carol J Levy; Amy B Criego; R Paul Wadwa; Erin C Cobry; Robert J Slover; Laurel H Messer; Cari Berget; Susan McCoy; Laya Ekhlaspour; Ryan S Kingman; Mary K Voelmle; Jennifer Boyd; Grenye O'Malley; Aimee Grieme; Kaisa Kivilaid; Krista Kleve; Bonnie Dumais; Todd Vienneau; Lauren M Huyett; Joon Bok Lee; Jason O'Connor; Eric Benjamin; Trang T Ly Journal: Diabetes Technol Ther Date: 2021-01-18 Impact factor: 6.118